Posts

Posted on

Citi Donates $9.4 Million to Education-Focused Non-Profit Organizations

Citi Donates $9.4 Million to Education-Focused Non-Profit Organizations

E-trading businesses support non-profit organizations for 2020 e 4 education campaign

LONDON–(BUSINESS WIRE)–
Citi today announced it has donated $9.4 million in support of education-focused non-profit organizations, as part of its 2020 e for education campaign.

Citi donated a percentage of the business proceeds traded electronically during the eight-week campaign from September to October.

The figure represents the highest annual amount raised since the initiative was launched. Since its inception in 2013, the campaign has raised $47 million in total.

“Our non-profit partners have persevered throughout the pandemic in their mission to provide equal access to a quality education for all children. We at Citi are humbled by their dedication and heartened by the response to the campaign, which serves as a testament to the impact of bringing people together to tackle these critical challenges.” – Itay Tuchman, Global Head of FX.

The education-focused non-profit organizations tackle childhood illiteracy and improve access to quality education.

Since its launch, the campaign has:

  • Raised over $47 million
  • Supported 606k + youth
  • Helped 530+ schools
  • Has spanned over 32 countries. With the inclusion of Teach For All, this will grow to over 70.

Further information can be found at: https://www.citifx.com/e4e/

Citi’s first E for Education campaign originated in FX in 2013 and the campaign has been expanded across Citi’s Markets and Securities e-trading businesses for the first time this year, including Commodities, Rates, Global Spread Products and, for the second year, Futures & Equities.

Citi works with 10 non-profit partners globally that support the right to education for all children, including Teach For All for the first time in 2020. The non-profit partners represent the global footprint of Citi’s Markets and Securities business.

2020 Partners:

Teach For All

A global network of organizations working to ensure all children have the education, support, and opportunity they need to fulfil their potential.

Malala Fund

Breaks down the barriers preventing more than 130 million girls around the world from going to school

Civic Builders

Builds environments fit for learning

Empower

Supports at-risk youth in education in EM countries

Fallen Patriots

Educates children who have lost a parent in the US Military

Place2Be

Enhances the wellbeing and prospects of children and their families by providing access to therapeutic and emotional support in schools

Reach the World

Makes the benefits of travel accessible to classrooms, inspiring youth to become more curious, confident global citizens

Room to Read

Gives children in EM countries access to education

Teach First

Develops teachers (and supports talented teachers to become inspiring and effective leaders)

Uncommon Schools

Opens schools in low-income areas

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management. Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

Media:

Rekha Jogia-Soni

Markets & Securities Services

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Finance Banking Professional Services Philanthropy Other Education Fund Raising Preschool Primary/Secondary Other Philanthropy Education

MEDIA:

Logo
Logo
Posted on

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline – PGEN

PR Newswire

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Precigen, Inc. f/k/a Intrexon Corporation (“Precigen” or the “Company”) (NASDAQ: PGEN).  The class action, filed in United States District Court for the Northern District of California, and docketed under 20-cv-07442, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired the Company’s securities between May 10, 2017 and March 2, 2020, both dates inclusive (the “Class Period”).  Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Precigen securities during the class period, you have until December 4, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 


[Click here for information about joining the class action]
 

Precigen f/k/a Intrexon purportedly operates in the synthetic biology field and creates biologically-based products.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was using pure methane as feedstock for its announced yields for its methanotroph bioconversion platform instead of natural gas; (ii) yields from natural gas as a feedstock were substantially lower than the aforementioned pure methane yields; (iii) because of the substantial price difference between pure methane and natural gas, pure methane was not a commercially viable feedstock; (iv) the Company was under investigation by the SEC; and (v) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

On March 2, 2020, during after-market hours, the Company filed a Form 10-K with the Securities and Exchange Commission (“SEC”), reporting the Company’s financial and operating results for the quarter and year ended December 31, 2019 (the “2019 10-K”).  The 2019 10-K stated the following regarding the SEC’s investigation:

[I]n October 2018, the Company received a subpoena from the Division of Enforcement of the SEC informing the Company of a non-public, fact-finding investigation concerning the Company’s disclosures regarding its methane bioconversion platform.

Following the filing of the 2019 10-K, the Company’s stock price fell $0.67 per share, or 17.14%, to close at $3.24 per share on March 3, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-precigen-inc-fka-intrexon-corporation-of-class-action-lawsuit-and-upcoming-deadline—pgen-301185471.html

SOURCE Pomerantz LLP

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Neovasc Inc. of Class Action Lawsuit and Upcoming Deadline – NVCN

PR Newswire

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) and certain of its officers. The class action, filed in United States District Court for the Southern District of New York, and docketed under 20-cv-09948, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Neovasc securities between October 10, 2018 and October 27, 2020, inclusive (the “Class Period”).  Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Neovasc securities during the Class Period, you have until January 5, 2021, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 


[Click here for information about joining the class action]
 

Neovasc is a specialty medical device company that develops, manufactures, and markets products for cardiovascular diseases, including the Tiara technology and the Reducer.  The Company’s Reducer is a medical device that treats refractory angina by altering blood flow in the heart’s circulatory system.

In December 2018, the Company filed a Q-Sub submission to the U.S. Food and Drug Administration (“FDA”) that contained safety and efficacy results from Neovasc’s clinical studies, as well as supporting data from peer-reviewed journals.

On February 20, 2019, Neovasc announced that, despite “Breakthrough Device Designation,” the FDA review team recommended that the Company collect further pre-market blinded data prior to submitting a Pre-Market Approval (“PMA”) application.

On November 1, 2019, the Company announced that it would submit a PMA application for the Reducer without gathering further evidence, against the FDA’s recommendation.  Neovasc claimed that “the clinical evidence already available will be sufficient to not further delay the availability of this Breakthrough medical device for the treatment of U.S. patients.”

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants failed to disclose to investors that: (i) Neovasc had overstated the viability of U.S. approval of the Reducer based on its “Breakthrough Device Designation” and prior studies supporting the Reducer’s efficacy and safety; (ii) the results of Neovasc’s clinical studies used to support approval for the Reducer in the U.S. contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (iii) the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (iv) blinding is critical when studying a placebo-responsive condition such as angina; (v) the lack of blinding assessment made the primary endpoint difficult to interpret; (vi) as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (vii) as a result, the Company’s PMA for Reducer was unlikely to be approved without additional clinical data; and (viii) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On October 28, 2020, before the market opened, the Company announced that an FDA advisory panel voted overwhelmingly against the safety and effectiveness of the Reducer.  The panel noted concerns with the Company’s clinical data, including “that the lack of blinding assessment made the primary endpoint difficult to interpret.”  As a result, the panel reached a consensus “that additional premarket randomized clinical data was necessary.”

On this news, the Company’s common share price fell $0.77 per share, or 42%, to close at $1.06 per share on October 28, 2020, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-neovasc-inc–of-class-action-lawsuit-and-upcoming-deadline—nvcn-301185468.html

SOURCE Pomerantz LLP

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Interface, Inc. of Class Action Lawsuit and Upcoming Deadline – TILE

PR Newswire

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Interface, Inc. (“Interface” or the “Company”) (NASDAQ: TILE) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05518, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Interface securities between March 2, 2018 and September 28, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Interface securities during the Class Period, you have until January 11, 2021, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 


[Click here for information about joining the class action]
 

Interface is a modular flooring company that designs, produces, and sells modular carpet products primarily in the Americas, Europe, and the Asia-Pacific.  The Company was founded in 1973 and is headquartered in Atlanta, Georgia.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (ii) consequently, Interface, inter alia, reported artificially inflated income and earnings per share (“EPS”) in 2015 and 2016; (iii) Interface and certain of its employees were under investigation by the Securities and Exchange Commission (“SEC”) with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC’s investigation, and downplayed the true scope of the Company’s wrongdoing and liability with respect to the SEC investigation; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On April 24, 2019, Defendants filed a current report on Form 8-K with the SEC, disclosing, inter alia, that Interface “received a letter in November 2017 from the [SEC] requesting that the Company voluntarily provide information and documents in connection with an investigation into the Company’s historical quarterly [EPS] calculations and rounding practices during the period 2014-2017″; that “[t]he Company subsequently received subpoenas from the SEC in February 2018, July 2018 and April 2019 requesting additional documents and information”; and that “[i]n the fourth quarter of 2018, the Company conducted at the SEC’s request an internal investigation into these and other related issues for seven quarters in 2015, 2016 and 2017.”

On this news, Interface’s stock price fell $1.43 per share, or 8.37%, to close at $15.66 per share on April 25, 2019.

Then, on September 28, 2020, the SEC announced the conclusion of its investigation into Interface’s historical quarterly EPS calculations and rounding practices.  Interface agreed to pay a $5 million fine to resolve the matter and was ordered to cease and desist from violating the federal securities laws.  In the SEC’s enforcement order issued that same day, the SEC also disclosed how, inter alia, “Interface employees caused Interface to produce documents in response to Commission investigative requests that were suggestive of contemporaneous support for journal entries that, in truth, did not exist at the time the entries were recorded,” and had modified certain documents after the SEC’s investigation began.

On this news, Interface’s stock price fell $0.20 per share, or 3.13%, over the following two trading sessions to close at $6.18 per share on September 29, 2020

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-interface-inc-of-class-action-lawsuit-and-upcoming-deadline—tile-301185462.html

SOURCE Pomerantz LLP

Posted on

Kepler and Infectious Media Join Forces to Create Global Innovation Leader

NEW YORK and LONDON, Dec. 03, 2020 (GLOBE NEWSWIRE) — Infectious Media, one of the firms that has powered the digital advertising revolution in Europe, announced today that it is joining Kepler Group, the US-based digital marketing pioneer that sits within the kyu Collective alongside companies such as IDEO, Sid Lee and SY Partners. This unites two transformative firms to create an industry leader with true global reach. The deal reflects the growing influence of next generation companies that help marketers navigate the seismic, technology-driven changes impacting how brands connect with consumers.

Data, platforms, advanced analytics, and speed are now the global foundations for modern marketing. This has driven advertisers to radically rethink their operating models, approach to tech, and role within the marketing value chain. In turn, they have turned to a new breed of marketing services firms that go beyond traditional media approaches to offer deep expertise on technology best practices, in-house team design and technical implementation, advanced measurement, and privacy.

This trend only accelerated as COVID-19 made brands even more reliant on e-commerce and data-driven marketing. As experts in these areas, Kepler and Infectious Media have both grown in 2020 while less technologically advanced marketing groups declined. 

The two firms have a shared focus on large-scale advertisers, and their combined client roster includes Hasbro, John Lewis, The New York Times, Pepsico, HSBC, and Uber. 

“We started talking about joining up two summers ago,” said Martin Kelly, Infectious Media’s CEO. “Both firms were award-winning leaders in their home markets. Both firms continued to grow in 2020. But we had each independently concluded that we needed to establish a global footprint to meet clients’ expanding needs. Combining forces presented a terrific way to accomplish that.”

“The extended dialogue provided us a chance to make sure the teams would fit well together,” added Rick Greenberg, Kepler CEO. “And that just became more obvious with every conversation, since both companies were built from day one to be among the most forward-thinking firms in the industry. With this acquisition, the amount of innovation talent we’re bringing together is simply awesome.”

Infectious Media will retain its brand name in the immediate term and adopt the Kepler name in a staged process. Together, the group will have nearly 400 professionals across offices in London, Singapore, New York, Philadelphia, Chicago, San Francisco, and Costa Rica. It will also retain the ability to leverage parent company Hakuhodo DY’s other digital units to provide specialized knowledge and capabilities, particularly in Japan and additional APAC markets. 

About Kepler:

Kepler, founded in 2012, provides advanced digital and database services to clients in financial services, retail, healthcare, media & entertainment, and other industries. Its core services revolve around helping clients use data to power more dynamic and personalized marketing — including digital media and advanced TV, CRM, database and marketing systems integration, and in-house media team design and activation. The company is a member of kyu, a strategic operating unit of Hakuhodo DY Holdings Inc. Fellow member companies include: IDEO, Sid Lee, SYPartners, Godfrey Dadich, and BEworks. More information can be found at www.keplergrp.com.

For more information from Kepler, contact:

Carolyn Powell
[email protected] 
+1.518.755.8165

About Infectious Media:

Infectious Media is a digital media specialist with offices in London and Singapore. The company was founded in 2008 at the start of the programmatic media revolution by Martin Kelly and Andy Cocker, and has grown to be one of the leading independent agencies in EMEA. The firm manages digital media activation for clients across display, social, search, video, and programmatic channels like connected TV and programmatic out-of-home. Based on this experience, it has a consulting unit that helps advertisers bring these activation functions in-house.

Infectious Media is one of the most awarded agencies in the UK. In recent years, it has placed 1st in the Deloitte Fast 50 for business growth and won numerous awards for client work, including The Exchange Wire and Drum Grand Prix Awards.

For more information from Infectious Media, contact:

Neil McKinnon
[email protected]
+44 7880 610 676 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/662d10a1-e801-4cdd-8577-af9f10679734



Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Evolus, Inc. of Class Action Lawsuit and Upcoming Deadline – EOLS

PR Newswire

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Evolus, Inc.  (“Evolus” or the “Company”) (NASDAQ: EOLS).  The class action, filed in United States District Court for the Southern District of New York, and docketed under 20-cv-09053, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Evolus securities between February 1, 2019 and July 6, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violation of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Evolus securities during the class period, you have until December 15, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 


[Click here for information about joining the class action]
 

Evolus is a Delaware corporation headquartered in Newport Beach, California.  The Company operates as a medical aesthetics company, and develops, produces, and markets clinical neurotoxins for the treatment of aesthetic concerns.  Evolus’ sole product is Jeuveau™, which is a purified botulinum toxin indicated for the temporary improvement in the appearance of moderate to severe frown lines in adults.  As such, Evolus directly competes with Botox®, which is manufactured by Allergan plc and Allergan Inc. (“Allergan”) and distributed by Medytox Inc. (“Medytox”).  Botox® has been the gold standard of the industry since its approval by the U.S. Food and Drug Administration (“FDA”) more than two decades ago.

Beginning in February 2019, Evolus embarked on a public campaign to hype the market right before the commercial launch of its sole leading product Jeuveau™.  To secure an aggressive growth and rapid influx of revenue, Defendants disseminated dozens of public statements in which they promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by Korean bioengineering company Daewoong through years of clinical research and millions of dollars’ worth of investment in research and development.  Among other things, Evolus promised investors that it would attain the number two U.S. market position within twenty-four months of launch.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau™ originated with and were misappropriated from Medytox; (ii) sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau™; (iii) as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau™; which in turn (iv) seriously threatened Evolus’ ability to commercialize Jeuveau™ in the U.S. and generate revenue; and (v) any revenues generated from the sale of Jeuveau™ were based on Evolus’ unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox.

The investing public learned the truth about Jeuveau™ on July 6, 2020, when the U.S. International Trade Commission (“ITC”) issued its Initial Final Determination in a case brought by Allergan and Medytox against Evolus, alleging that Evolus stole certain trade secrets to develop Jeuveau™.  Coming as a great surprise to unsuspecting investors, the ITC Judge found that Evolus misappropriated the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture.  Additionally, the ITC Judge recommended a ten-year-long ban on Evolus’ ability to import Jeuveau™ into the U.S. and a ten-year-long cease-and-desist order preventing Evolus from selling Jeuveau™ in the U.S.

This news caused a precipitous and immediate decline in the price of Evolus shares, which fell 37% over the course of two trading days, to close at $3.35 per share on July 8, 2020, on unusually high trading volume.  Following the news of the ITC’s Initial Final Determination and the subsequent price drop of Evolus’ common shares, several securities analysts downgraded Evolus’ rating and significantly lowered the Company’s price target.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-evolus-inc-of-class-action-lawsuit-and-upcoming-deadline—eols-301185458.html

SOURCE Pomerantz LLP

Posted on

Himax Ultralow Power WE-I Plus Endpoint AI Development Board available at SparkFun to enable AI everywhere

TAINAN, Taiwan, Dec. 03, 2020 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced its WE-I Plus EVB, an Endpoint AI Development Board that incorporates Himax’s ultralow power HX6537-A WE-I Plus AI processor and HM0360 always-on image sensor, is now available at SparkFun, a specialized online retail store which caters to diverse demands from developers for Endpoint AI deployment.

High performance Endpoint AI solution with ultralow power consumption

The WE-I Plus processor is designed to accommodate a wide selection of TinyML Neural Network models with programmable DSP running up to 400MHz clock and 2MB internal SRAM. WE-I Plus supports TensorFlow Lite for Microcontrollers framework and is able to run inferences such as open-source Google Examples, including “Hello World”, “Micro Speech”, “Person Detection”, and “Magic Wand”, all available at Google’s GitHub. It is fully optimized in computer vision applications and has demonstrated to be among the lowest in power consumption using the “Person Detection” example. WE-I Plus, coupled with Himax’s VGA sensor, runs the example inference and operates in power consumption as low as 2.5mW with model inference time of less than 35ms.

TinyML developer friendly Endpoint AI Development Board at SparkFun

Developers now get easy access to Himax’s leading technologies with WE-I Plus EVB available at the SparkFun online retail store for Endpoint AI system development, ultimately enabling the innovation of life-changing use cases. The all-in-one WE-I Plus EVB includes AI processor, HM0360 AoS VGA camera, 2 microphones and a 3-axis accelerometer to perform vision, voice, and vibration detection and recognition. It builds in FTDI USB-to-SPI/ I2C/ UART bridge for flash programming interfacing and message/ debug print/ metadata output. It also features two LEDs to illustrate classification results. In addition, an expansion header with I2C and GPIOs interface is offered to allow connections to external sensors or devices. Datasheets of EVB, processor and sensors are available for download on the SparkFun website.

Reference Link of Himax WE-I Plus EVB/ Endpoint AI Development Board at SparkFun
https://www.SparkFun.com/products/17256

Reference Link of open-source examples of Google TensorFlow Lite for Microcontrollers at Google GitHub

Reference Link of Himax Always-On Smart Sensing
https://www.himax.com.tw/products/intelligent-sensing/always-on-smart-sensing/

About Himax Technologies, Inc.

Himax Technologies, Inc. (NASDAQ: HIMX) is a fabless semiconductor solution provider dedicated to display imaging processing technologies. Himax is a worldwide market leader in display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Additionally, Himax designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration (TDDI) single-chip solutions, LED driver ICs, power management ICs, scaler products for monitors and projectors, tailor-made video processing IC solutions, silicon IPs and LCOS micro-displays for augmented reality (AR) devices and heads-up displays (HUD) for automotive. The Company also offers digital camera solutions, including CMOS image sensors and wafer level optics for AR devices, 3D sensing and machine vision, which are used in a wide variety of applications such as mobile phones, tablets, laptops, TVs, PC cameras, automobiles, security, medical devices and Internet of Things. Founded in 2001 and headquartered in Tainan, Taiwan, Himax currently employs around 2,000 people from three Taiwan-based offices in Tainan, Hsinchu and Taipei and country offices in China, Korea, Japan, Israel and the US. Himax has 2,915 patents granted and 551 patents pending approval worldwide as of September 30th, 2020. Himax has retained its position as the leading display imaging processing semiconductor solution provider to consumer electronics brands worldwide.


http://www.himax.com.tw

Forward Looking Statements

Factors that could cause actual events or results to differ materially include, but not limited to, general business and economic conditions and the state of the semiconductor industry; market acceptance and competitiveness of the driver and non-driver products developed by the Company; demand for end-use applications products; reliance on a small group of principal customers; the uncertainty of continued success in technological innovations; our ability to develop and protect our intellectual property; pricing pressures including declines in average selling prices; changes in customer order patterns; changes in estimated full-year effective tax rate; shortages in supply of key components; changes in environmental laws and regulations; exchange rate fluctuations; regulatory approvals for further investments in our subsidiaries; our ability to collect accounts receivable and manage inventory and other risks described from time to time in the Company’s SEC filings, including those risks identified in the section entitled “Risk Factors” in its Form 20-F for the year ended December 31, 2019 filed with the SEC, as may be amended.

Company Contacts:

Eric Li, Chief IR/PR Officer

Himax Technologies, Inc.
Tel: +886-6-505-0880 Ext. 60145
Fax: +886-2-2314-0877
Email: [email protected]
www.himax.com.tw

Karen Tiao, Investor Relations

Himax Technologies, Inc.
Tel: +886-2-2370-3999 Ext. 22326
Fax: +886-2-2314-0877
Email: [email protected]
www.himax.com.tw

 



Posted on

Amadeus Expands Partnership with Couchbase to Help Customers Dynamically Scale and Adapt to Changing Travel Demand

Leading cloud-native database allows Amadeus to flexibly scale services, better integrate with third parties, and enable greater personalization for customers

LONDON, Dec. 03, 2020 (GLOBE NEWSWIRE) — With a keen desire to get back on the road, travelers are cautiously resuming to search for and book flights and hotels. But travel players are facing a challenging new reality – one where performance, flexible operations and personalized service are quickly taking on a whole new meaning in order to remain relevant. 

To this end, Amadeus has extended its partnership with  Couchbase, the creator of the enterprise-class, multi-cloud to edge NoSQL database. The new multi-year agreement will see Amadeus using Couchbase to dynamically scale its levels of service and continue to deploy applications quickly. Couchbase’s versatile and cloud-agnostic database already powers a number of Amadeus applications across search, shopping and merchandising for airline and hotel customers, as well as Traveler-DNA (former Customer Experience Management) – and Amadeus will be adding more in line with evolving industry needs. 

Expanding its use of Couchbase is part of Amadeus’s strategy to continue taking advantage of the cloud and developing new applications to support the industry. Couchbase’s features such as integration with Kubernetes are an important element of this strategy, as well as its ease of use for developers, coupled with the agility and scalability to help solutions ramp up and complete faster. 

As a result, Amadeus developers have quickly adopted Couchbase, seeing a significantly decreased time-to-market thanks to reduced data friction issues and an easier integration with third-party partners. This represents a close fit with Amadeus’ platform approach – allowing engineers to solve a growing number of complex business challenges quickly and efficiently. Ultimately this partnership opens the way towards innovative solutions that can offer greater personalization, an essential need in the current environment.

“Supporting the recovery of the travel industry is our prime objective. We are currently in a highly challenging environment, where the industry is having to react at speed to changing traveler needs and demands.” said Sylvain Roy, SVP, Technology Platforms & Engineering, Amadeus.

Roy continued, “The ability to develop new travel applications and functionality quickly, whilst ensuring those that our customers already rely on continue operating at peak effectiveness, is critical. Couchbase’s database makes it much simpler for our engineers to focus on what they do best: solving our customers’ business challenges – all the while improving collaboration with partners and developers. Our growing partnership will help us deliver the enterprise-class performance, scale, flexibility, reliability and traveler focus that our customers need, enabling us also to innovate more freely in key areas such as merchandising, NDC or loyalty.”

“Amadeus is one of our largest and most important customers, and how they have used our technology is nothing short of impressive,” said Matt Cain, President and CEO, Couchbase. “Amadeus has built a truly scalable platform that enables them to dynamically adjust service levels as needed and simultaneously drive future innovation aligned to their digital transformation initiatives. We are proud of our partnership with Amadeus and the role we’ve been able to play in helping them provide delightful experiences for their customers in ever-changing circumstances. We look forward to further supporting them in powering the recovery and continued reinvention of the travel industry.”

 

About Couchbase

Unlike other NoSQL databases, Couchbase provides an enterprise-class, multicloud to edge database that offers the robust capabilities required for business-critical applications on a highly scalable and available platform. As a distributed cloud-native database, Couchbase runs in modern dynamic environments and on any cloud, either customer-managed or fully managed as-a-service. Couchbase is built on open standards, combining the best of NoSQL with the power and familiarity of SQL, to simplify the transition from mainframe and relational databases. 

Couchbase has become pervasive in our everyday lives; our customers include industry leaders Amadeus, American Express, Carrefour, Cisco, Comcast/Sky, Disney, eBay, LinkedIn, Marriott, Tesco, Tommy Hilfiger, United, Verizon, as well as hundreds of other household names. For more information, visit www.couchbase.com.

About Amadeus

Travel powers progress. Amadeus powers travel. Amadeus’ solutions connect travelers to the journeys they want through travel agents, search engines, tour operators, airlines, airports, hotels, cars and railways. 

We have developed our technology in partnership with the travel industry for over 30 years. We combine a deep understanding of how people travel with the ability to design and deliver the most complex, trusted, critical systems our customers need. We help connect over 1.6 billion people a year to local travel providers in over 190 countries. 

We are one company, with a global mindset and a local presence wherever our customers need us. 

Our purpose is to shape the future of travel. We are passionate in our pursuit of better technology that makes better journeys. 

Amadeus is an IBEX 35 company, listed on the Spanish Stock Exchange under AMS.MC. The company is also part of the EuroStoxx50 and has been recognized by the Dow Jones Sustainability Index for the last eight years. 

To find out more about Amadeus, visit www.amadeus.com.

  

© 2020 Couchbase, Inc.  All rights reserved.  Couchbase, the Couchbase logo, and the names and marks associated with Couchbase’s products are trademarks of Couchbase, Inc.  All other trademarks are the property of their respective owners. 



Christina Knittel
Couchbase
7752092461
[email protected]

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPT

PR Newswire

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc.  (“Intercept” or the “Company”) (NASDAQ: ICPT) and certain of its officers.  The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05377, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Intercept securities between September 28, 2019 and October 7, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Intercept securities during the class period, you have until January 4, 2021, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 


[Click here for information about joining the class action]
 

Intercept is a biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the U.S.

Intercept’s lead product candidate is Ocaliva (obeticholic acid (“OCA”)), a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (“PBC”), a rare and chronic liver disease, in combination with ursodeoxycholic acid in adults.  The Company is also developing OCA for various other indications, including nonalcoholic steatohepatitis (“NASH”).

In 2016, the U.S. Food and Drug Administration (“FDA”) granted accelerated approval of Ocaliva for treating PBC.

Then, in late 2017, both Intercept and the FDA issued warnings concerning the risk of overdosing patients with the drug, and multiple reports of severe liver injuries and deaths linked with its use.

Despite these concerns, Defendants continued to tout Ocaliva sales and purported benefits, and its potential indication for treating various other medical conditions.  For example, just two years later, in September 2019, Intercept submitted a New Drug Application (“NDA”) to the FDA for OCA to treat patients with liver fibrosis due to NASH.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (ii) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

On May 22, 2020, Intercept reported that the FDA “has notified Intercept that its tentatively scheduled June 9, 2020 advisory committee meeting (AdCom) relating to the company’s [NDA] for [OCA] for the treatment of liver fibrosis due to [NASH] has been postponed” to “accommodate the review of additional data requested by the FDA that the company intends to submit within the next week.”

On this news, Intercept’s stock price fell $11.18 per share, or 12.19%, to close at $80.51 per share on May 22, 2020.

On June 29, 2020, Intercept issued a press release announcing that the FDA had issued a Complete Response Letter (“CRL”) rejecting the Company’s NDA for Ocaliva for the treatment of liver fibrosis due to NASH.  According to that press release, “[t]he CRL indicated that, based on the data the FDA has reviewed to date,” the FDA “has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH.”  The press release further advised, among other things, that the “[t]he FDA recommends that Intercept submit additional post-interim analysis efficacy and safety data from the ongoing REGENERATE study in support of potential accelerated approval and that the long-term outcomes phase of the study should continue.”

On this news, Intercept’s stock price fell $30.79 per share, or 39.73%, to close at $46.70 per share on June 29, 2020.

Then, on October 8, 2020, news outlets reported that Intercept was “facing an investigation from the [FDA] over the potential risk of liver injury in patients taking Ocaliva, [Intercept’s] treatment for primary biliary cholangitis, a rare, chronic liver disease.”

On this news, Intercept’s stock price fell $3.30 per share, or 8.05%, to close at $37.69 per share on October 8, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-intercept-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadline—icpt-301185456.html

SOURCE Pomerantz LLP

Posted on

Leumi Named 2020 Bank of the Year in Israel by The Banker

PR Newswire

TEL AVIV, Israel, Dec. 3, 2020 /PRNewswire/ — Bank Leumi (TASE: LUMI) has been awarded Bank of the Year in Israel for 2020 by the prestigious magazine The Banker, part of the Financial Times Group. This is the third consecutive time and the ninth time in total that Leumi has won the distinguished title. Leumi was selected by a professional panel of judges who examined the Bank’s financial results, business achievements, investment in technology, strategic initiatives and response to COVID-19.

“Congratulations to Bank Leumi for scooping the accolade for Israel in The Banker‘s Bank of the Year Awards 2020,” says Joy Macknight, managing editor of The Banker. “In addition to the bank’s strong performance during a tumultuous period, Bank Leumi’s quick and innovative response to the COVID-19 pandemic, including launching a completely digital mortgage process, impressed the judges. It clearly demonstrates that the efforts and resources the bank has made in its digital transformation are reaping results.”

Leumi President & CEO, Hanan Friedman said: “The win is further acknowledgement of the professionalism and dedication of Leumi’s employees, and their commitment to providing the best response to our customers’ needs even in the complex environment in which we operate. As COVID-19 started to spread in early 2020, Leumi was determined to provide a continuous response to all of our customers’ need. In this context, it swiftly migrated to working remotely on all fronts. Our main goal was to allow customers to perform complex transactions from home, even during lockdown. The new reality led to a leap in digital adoption across all customer segments, even by those considered to be non-digital oriented. As such, our ‘Total Digital Mortgage’ service was embraced by many customers, providing Leumi clear competitive edge. Prior to COVID-19, we prepared Leumi for tomorrow’s banking, but the pandemic has significantly shortened the transition period. We have swiftly adapted our operating model in terms of customer experience, technological capabilities and banker skills, in order to maintain Leumi’s position at the forefront of Israeli banking”.

Bank Leumi
 (TASE: LUMI) is Israel’s leading banking corporation, providing comprehensive financial services and holding an approximate 30% domestic market share. Headquartered in Tel Aviv, Leumi has a presence in key financial centers such as London and New York. For the quarter ended September 30 2020, Leumi reported a net profit of NIS 750 Million ($218 million), with total assets reaching NIS 528.1 billion ($153 billion).

The data in this press release has been converted into US dollars solely for convenience purposes, at the representative exchange rate published by the Bank of Israel on September 30, 2020, NIS 3.441.

For more information visit 

www.leumi.co.il

 or contact Daphna Golden, VP, Head of Investor Relations, at 

[email protected]

.

 

Cision View original content:http://www.prnewswire.com/news-releases/leumi-named-2020-bank-of-the-year-in-israel-by-the-banker-301185508.html

SOURCE Bank Leumi